Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

1区 · 医学

Article

作者: Perrior, Trevor ; Newton, Gary ; Te Lintel Hekkert, Maaike ; Yan, Robert ; Lane, Charlotte A L ; Aqil, Rehan ; Cawkill, Darren ; Downham, Robert ; Chapman, Kathryn ; Whitlock, Gavin ; Schneider, Michael D ; Merkus, Daphne ; Duncker, Dirk J

AbstractReducing infarct size (IS) by interfering with mechanisms for cardiomyocyte death remains an elusive goal. DMX-5804, a selective inhibitor of the stress-activated kinase MAP4K4, suppresses cell death in mouse myocardial infarction (MI), human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs), and 3D human engineered heart tissue, whose fidelity to human biology is hoped to strengthen the route to clinical success. Here, DMX-10001, a soluble, rapidly cleaved pro-drug of DMX-5804, was developed for i.v. testing in large-mammal MI. Following pharmacodynamic studies, a randomized, blinded efficacy study was performed in swine subjected to LAD balloon occlusion (60 min) and reperfusion (24 h). Thirty-six animals were enrolled; 12 were excluded by pre-defined criteria, death before infusion, or technical issues. DMX-10001 was begun 20 min before reperfusion (30 min, 60 mg/kg/h; 23.5 h, 17 mg/kg/h). At all times tested, beginning 30 min after the start of infusion, DMX-5804 concentrations exceeded > fivefold the levels that rescued hPSC-CMs and reduced IS in mice after oral dosing with DMX-5804 itself. No significant reduction occurred in IS or no-reflow corrected for the area at ischemic risk, even though DMX-10001 reduced IS, expressed in grams or % of LV mass, by 27%. In summary, a rapidly cleaved pro-drug of DMX-5804 failed to reduce IS in large-mammal MI, despite exceeding the concentrations for proven success in both mice and hPSC-CMs.

2019-04-01·Cell Stem Cell1区 · 医学

MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo

1区 · 医学

Article

作者: Chapman, Kathryn ; Aqil, Rehan ; Pavanello, Lorenzo ; Tralau-Stewart, Catherine ; Noseda, Michela ; Sampson, Robert D ; Perrior, Trevor ; Harada, Mutsuo ; Newton, Gary ; Sano, Motoaki ; Maifoshie, Evie ; Entman, Mark L ; Fiedler, Lorna R ; Wang, Sam C ; Sanmugalingam, Devika ; Golforoush, Pelin Arabacilar ; Paiva, Marta Abreu ; Low, Caroline M R ; Habib, Josef ; Schneider, Michael D ; Stuckey, Daniel J ; Jarvis, Ashley ; Jenkins, Micaela ; Xie, Min ; Michael, Lloyd H ; Song, Weihua ; Harding, Sian E ; Faust, Dörte ; Kanayaganam, Sunthar ; Tan, Tse-Hua ; Bellahcene, Mohamed ; Yan, Robert ; Narasimhan, Priyanka ; Taffet, George E

Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival.

Cardiovascular Diabetology

MAP4K4 exacerbates cardiac microvascular injury in diabetes by facilitating S-nitrosylation modification of Drp1

Article

作者: Yang, Fan ; Lu, Jian ; Guan, Bo ; Yan, Xiaopei ; Li, Su ; Zhang, Jun ; Chen, Yuqiong ; Kong, Xiangqing ; Huang, Chao ; Li, Yafei ; Chen, Chao ; Zhang, Nannan ; Chen, Zhangwei ; Wang, Jiankang ; Du, Yingqiang

AbstractDynamin-related protein 1 (Drp1) is a crucial regulator of mitochondrial dynamics, the overactivation of which can lead to cardiovascular disease. Multiple distinct posttranscriptional modifications of Drp1 have been reported, among which S-nitrosylation was recently introduced. However, the detailed regulatory mechanism of S-nitrosylation of Drp1 (SNO-Drp1) in cardiac microvascular dysfunction in diabetes remains elusive. The present study revealed that mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) was consistently upregulated in diabetic cardiomyopathy (DCM) and promoted SNO-Drp1 in cardiac microvascular endothelial cells (CMECs), which in turn led to mitochondrial dysfunction and cardiac microvascular disorder. Further studies confirmed that MAP4K4 promoted SNO-Drp1 at human C644 (mouse C650) by inhibiting glutathione peroxidase 4 (GPX4) expression, through which MAP4K4 stimulated endothelial ferroptosis in diabetes. In contrast, inhibition of MAP4K4 via DMX-5804 significantly reduced endothelial ferroptosis, alleviated cardiac microvascular dysfunction and improved cardiac dysfunction in db/db mice by reducing SNO-Drp1. In parallel, the C650A mutation in mice abolished SNO-Drp1 and the role of Drp1 in promoting cardiac microvascular disorder and cardiac dysfunction. In conclusion, our findings demonstrate that MAP4K4 plays an important role in endothelial dysfunction in DCM and reveal that SNO-Drp1 and ferroptosis activation may act as downstream targets, representing potential therapeutic targets for DCM.

100 项与 DMX-5804 相关的药物交易

登录后查看更多信息